Report ID :10346706 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
Global pharmaceutical CRO market will reach $104.4 billion by 2030, growing by 8.1% annually over 2020-2030 driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 85 tables and 77 figures, this 168-page report “Global Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmaceutical CRO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical CRO market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Region.
Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services
Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global pharmaceutical CRO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
